p53 pS37 Antibody, anti-human, REAfinity™
Synonyms: TP53, BCC7, LFS1, TRP53, NY-CO-13
RECOMBINANT
Clone:
REA424 | J159-641.79
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
ICFC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for p53 pS37 Antibody, anti-human, REAfinity™

Intracellular flow cytometry applications
APC
PE
Recommended dilution:
1:11
Remark:
The antibody is suited for staining of formaldehyde-fixed cells.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-106-599, 130-106-556
Description:
Human SU-DH-L1 lymphoma cells were fixed and permeabilized using the Cell Signaling Buffer Set A. Cells were then stained with Anti-p53 pS37 antibodies or with the corresponding REA Control (I) antibodies (left peak) and analyzed by flow cytometry using the MACSQuant® Analyzer. Cell debris were excluded from the analysis based on scatter signals.

Application image
Specifications for p53 pS37 Antibody, anti-human, REAfinity™
Overview

Clone REA424 recognizes the human cellular tumor antigen p53 phosphorylated at serine 37 (pS37). The p53 protein is an important regulator of cell growth and, thus, functions as a tumor suppressor in many tumor types. The p53 tumor suppressor gene is altered or deleted in most solid human tumors. It is tightly regulated and plays a critical role in the cellular response to environmental stress. Upon a cell's exposure to stress, such as hypoxia or genomic damage, the p53 protein is expressed at high levels and is post-translationally modified. These modifications, which include phosphorylation, acetylation, and glycosylation occur rapidly and lead to the activation of p53, resulting in either G1 growth arrest or programmed cell death. Following DNA damage, p53 is phosphorylated on serine residues 15, 20, 33, and 37 within the amino-terminal domain. These phosphorylation events are thought to play a key role in regulating p53 stability and activity. p53 is phosphorylated at S37 in response to both ultraviolet (UV)- and γ-irradiation and may have different functions in response to these two different DNA-damaging treatments. Phosphorylation at this site following UV-irradiation is needed to maintain p53 stability, since mutation of S37 to alanine impaired the accumulation of p53 after exposing cells to UV.

Additional information: Clone REA424 displays negligible binding to Fc receptors.

Alternative names

TP53, BCC7, LFS1, TRP53, NY-CO-13

Detailed product information

Technical specifications

Clone
REA424
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (I), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
p53 pS37
Molecular mass of antigen [kDa]
43
Distribution of antigen
other
Entrez Gene ID
RRID
AB_2653142, AB_2653144, AB_2653143, AB_2653145

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for p53 pS37 Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

Citations for p53 pS37 Antibody, anti-human, REAfinity™
Publications
  1. Lees-Miller, S. P. et al. (1992) Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53. Mol. Cell. Biol. 12 (11): 5041-5049
  2. Li, D. W. et al. (2006) Protein serine/threonine phosphatase-1 dephosphorylates p53 at Ser-15 and Ser-37 to modulate its transcriptional and apoptotic activities. Oncogene 25 (21): 3006-3022
  3. Zakut-Houri, R. et al. (1985) Human p53 cellular tumor antigen: cDNA sequence and expression in COS cells. EMBO J. 4 (5): 1251-1255